centrosomal protein 85LGenealiases: C6orf204 · LIS10 · NY-BR-15 · bA57K17.2
Q-omics provides the consensus-scored CEP85L profile across patient tissues and cancer cell-line models. CEP85L expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CEP85L is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, CEP85L RNA expression shows 20,583 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight SKCM, KIRC, and KIRP as cancer lineages where CEP85L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEP85L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEP85L survival associations across molecular data types. CEP85L RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEP85L RNA expression–survival associations across cancer types. High CEP85L expression shows unfavorable associations in LUSC and LUAD, but favorable associations in SKCM, UCS, ACC and CHOL. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CEP85L RNA expression.
This table summarizes CEP85L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CEP85L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEP85L shows lower tumor expression in THCA, BLCA, LUSC, COAD and KICH and higher tumor expression in KIRC. The KIRC box plot shows higher CEP85L RNA expression in tumor versus normal tissue (log2 FC = +0.506, t-test p < 0.001).
This table shows molecular features associated with CEP85L in patient tissues and cancer cell lines. In patient samples, CEP85L shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, CEP85L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
